{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:33:02Z","timestamp":1787067182814,"version":"build-2736575974"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T00:00:00Z","timestamp":1489708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The primary objective was to determine whether mid-treatment ultrasound measurements of index breast tumors and index axillary nodes of different cancer subtypes associate with residual cancer burden (RCB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with invasive breast cancer who underwent neoadjuvant chemotherapy and had pre-treatment and mid-treatment breast and axillary ultrasound were included in this single-institution, retrospective cohort study. Linear regression analysis assessed associations between RCB with (a) change in index breast tumor size, (b) change in index node size, and (c) absolute number of abnormal nodes at mid-treatment. Multivariate linear regression was used to calculate best-fit models for RCB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred fifty-nine patients (68 triple negative breast cancer [TNBC], 45 hormone receptor [HR]+\/human epidermal growth factor receptor 2 [HER2]\u2212, and 46 HR\u2212\/HER2+) were included. Median age at diagnosis was 50 years, range 30\u201376. Median tumor size was 3.4 cm, range 0.9\u201310.4. Pathological complete response\/RCB-I rates were 36.8% (25\/68) for TNBC patients, 24.4% (11\/45) for HR+\/HER2\u2212 patients, and 71.7% (33\/46) for HR\u2212\/HER2+ patients. Linear regression analyses demonstrated associations between percent change in tumor ultrasound measurements at mid-treatment with RCB index score in TNBC and HR+\/HER2\u2212 (p\u2009&amp;lt;\u2009.05) but not in HR\u2212\/HER2+ (p\u2009&amp;gt;\u2009.05) tumors and an association between axillary ultrasound assessment of number of abnormal nodes at mid-treatment with RCB index score across all subtypes (p\u2009&amp;lt;\u2009.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Performance characteristics of breast ultrasound associated with RCB vary by cancer subtype, whereas the performance characteristics of axillary ultrasound associated with RCB are consistent across cancer subtype. Breast and axillary ultrasound may be valuable in monitoring response to neoadjuvant therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2016-0307","type":"journal-article","created":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T22:58:25Z","timestamp":1489791505000},"page":"394-401","source":"Crossref","is-referenced-by-count":26,"title":["Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype"],"prefix":"10.1093","volume":"22","author":[{"given":"Rosalind P.","family":"Candelaria","sequence":"first","affiliation":[{"name":"Department of Diagnostic Radiology Unit 1350"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland L.","family":"Bassett","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Unit 1411"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Fraser","family":"Symmans","sequence":"additional","affiliation":[{"name":"Department of Pathology, Unit 1445"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maheshwari","family":"Ramineni","sequence":"additional","affiliation":[{"name":"Department of Pathology, Unit 1445"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy L.","family":"Moulder","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, Unit 1354"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry M.","family":"Kuerer","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, Unit 1434 The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair M.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, Unit 1434 The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Tse","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology Unit 1350"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,3,17]]},"reference":[{"key":"2021122507522728200_onco12092-bib-0001","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","article-title":"Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27","volume":"24","author":"Bear","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122507522728200_onco12092-bib-0002","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/jnci\/dji021","article-title":"Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis","volume":"97","author":"Mauri","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2021122507522728200_onco12092-bib-0003","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/j.ejca.2011.06.014","article-title":"Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients","volume":"47","author":"Kong","year":"2011","journal-title":"Eur J Cancer"},{"key":"2021122507522728200_onco12092-bib-0004","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.1999.17.2.460","article-title":"Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy","volume":"17","author":"Kuerer","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122507522728200_onco12092-bib-0005","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122507522728200_onco12092-bib-0006","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/modpathol.2015.74","article-title":"Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: Recommendations from an international working group","volume":"28","author":"Provenzano","year":"2015","journal-title":"Mod Pathol"},{"key":"2021122507522728200_onco12092-bib-0007","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.amjsurg.2009.03.012","article-title":"Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer","volume":"199","author":"Keune","year":"2010","journal-title":"Am J Surg"},{"key":"2021122507522728200_onco12092-bib-0008","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00330-004-2246-z","article-title":"Locally advanced breast cancer: Comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy","volume":"14","author":"Londero","year":"2004","journal-title":"Eur Radiol"},{"key":"2021122507522728200_onco12092-bib-0009","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1007\/s00330-006-0317-z","article-title":"Monitoring therapeutic efficacy in breast carcinomas","volume":"16","author":"Tardivon","year":"2006","journal-title":"Eur Radiol"},{"key":"2021122507522728200_onco12092-bib-0010","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00130404-200605000-00010","article-title":"Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer","volume":"12","author":"Kwong","year":"2006","journal-title":"Cancer J"},{"key":"2021122507522728200_onco12092-bib-0011","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13244-013-0219-y","article-title":"The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: A systematic review","volume":"4","author":"Lobbes","year":"2013","journal-title":"Insights Imaging"},{"key":"2021122507522728200_onco12092-bib-0012","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2214\/ajr.179.5.1791193","article-title":"Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy","volume":"179","author":"Partridge","year":"2002","journal-title":"AJR Am J Roentgenol"},{"key":"2021122507522728200_onco12092-bib-0013","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1245\/s10434-011-1590-x","article-title":"Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer","volume":"18","author":"Guarneri","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"2021122507522728200_onco12092-bib-0014","doi-asserted-by":"crossref","first-page":"868","DOI":"10.2214\/ajr.184.3.01840868","article-title":"Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer","volume":"184","author":"Yeh","year":"2005","journal-title":"AJR Am J Roentgenol"},{"key":"2021122507522728200_onco12092-bib-0015","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/jso.20856","article-title":"Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy","volume":"96","author":"Segara","year":"2007","journal-title":"J Surg Oncol"},{"key":"2021122507522728200_onco12092-bib-0016","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/annonc\/mdn683","article-title":"Age and HER2 expression status affect MRI accuracy in predicting residual tumour extent after neo-adjuvant systemic treatment","volume":"20","author":"Moon","year":"2009","journal-title":"Ann Oncol"},{"key":"2021122507522728200_onco12092-bib-0017","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1200\/JCO.2010.31.1258","article-title":"Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: Relevance of breast cancer subtype","volume":"29","author":"Loo","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122507522728200_onco12092-bib-0018","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"Wolff","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"2021122507522728200_onco12092-bib-0019","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10549-011-1454-x","article-title":"Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients","volume":"127","author":"Gounaris","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"2021122507522728200_onco12092-bib-0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2021122507522728200_onco12092-bib-0021","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122507522728200_onco12092-bib-0022","year":"2015"},{"key":"2021122507522728200_onco12092-bib-0024","doi-asserted-by":"crossref","first-page":"646","DOI":"10.2214\/AJR.07.2460","article-title":"Cortical morphologic features of axillary lymph nodes as a predictor of metastasis in breast cancer: In vitro sonographic study","volume":"191","author":"Bedi","year":"2008","journal-title":"AJR Am J Roentgenol."},{"key":"2021122507522728200_onco12092-bib-0025","volume-title":"Model selection and multimodel inference: A practical information-theoretic approach","author":"Burnham","year":"2002"},{"key":"2021122507522728200_onco12092-bib-0026","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s12282-010-0235-4","article-title":"MR and US imaging for breast cancer patients who underwent conservation surgery after neoadjuvant chemotherapy: Comparison of triple negative breast cancer and other intrinsic subtypes","volume":"18","author":"Nakahara","year":"2011","journal-title":"Breast Cancer"},{"key":"2021122507522728200_onco12092-bib-0027","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1148\/radiol.11110814","article-title":"Breast cancer: Evaluation of response to chemotherapy with 3.0-T MR imaging","volume":"261","author":"Chen","year":"2011","journal-title":"Radiology"},{"key":"2021122507522728200_onco12092-bib-0028","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/cncr.23130","article-title":"MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy","volume":"112","author":"Chen","year":"2008","journal-title":"Cancer"},{"key":"2021122507522728200_onco12092-bib-0029","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/SLA.0b013e3182686bd9","article-title":"Breast cancer molecular phenotype and the use of HER2-targeted agents influence the accuracy of breast MRI after neoadjuvant chemotherapy","volume":"257","author":"Moon","year":"2013","journal-title":"Ann Surg"},{"key":"2021122507522728200_onco12092-bib-0030","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/annonc\/mdv161","article-title":"Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration","volume":"26","author":"Bossuyt","year":"2015","journal-title":"Ann Oncol"},{"key":"2021122507522728200_onco12092-bib-0031","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1148\/radiol.2015150013","article-title":"Neoadjuvant chemotherapy for breast cancer: Functional tumor volume by MR imaging predicts recurrence-free survival-results from the ACRIN 6657\/CALGB 150007 I-SPY 1 TRIAL","volume":"279","author":"Hylton","year":"2016","journal-title":"Radiology"},{"key":"2021122507522728200_onco12092-bib-0032","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clbc.2012.01.009","article-title":"Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile","volume":"12","author":"Kuzucan","year":"2012","journal-title":"Clin Breast Cancer"},{"key":"2021122507522728200_onco12092-bib-0033","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10549-016-3862-4","article-title":"Extent of ductal carcinoma in situ according to breast cancer subtypes: A population-based cohort study","volume":"158","author":"Doebar","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2021122507522728200_onco12092-bib-0034","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2214\/AJR.13.12221","article-title":"Correlation between sonographic findings and clinicopathologic and biologic features of pure ductal carcinoma in situ in 691 patients","volume":"204","author":"Scoggins","year":"2015","journal-title":"AJR Am J Roentgenol"},{"key":"2021122507522728200_onco12092-bib-0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4103\/0019-509X.12339","article-title":"Complete axillary conversion after neoadjuvant chemotherapy in locally advanced breast cancer: A step towards conserving axilla?","volume":"41","author":"Arimappamagan","year":"2004","journal-title":"Indian J Cancer"},{"key":"2021122507522728200_onco12092-bib-0036","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1245\/s10434-013-3118-z","article-title":"Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer","volume":"20","author":"Hieken","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"2021122507522728200_onco12092-bib-0037","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejrad.2014.09.020","article-title":"Noninvasive nodal restaging in clinically node positive breast cancer patients after neoadjuvant systemic therapy: A systematic review","volume":"84","author":"Schipper","year":"2015","journal-title":"Eur J Radiol"},{"key":"2021122507522728200_onco12092-bib-0038","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00259-013-2515-7","article-title":"Sequential (18)F-FDG PET\/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy","volume":"41","author":"Koolen","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2021122507522728200_onco12092-bib-0039","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1200\/JCO.2014.57.8401","article-title":"Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: Results from the American College of Surgeons Oncology Group Z1071 Trial (Alliance)","volume":"33","author":"Boughey","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122507522728200_onco12092-bib-0040","article-title":"Women\u2019s triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer using molecular triaging and diagnostic imaging to guide neoadjuvant therapy. Poster presented at: 2015","author":"Mitri","year":"2015","journal-title":"San Antonio Breast Cancer Symposium."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2016-0307","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2016-0307","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/4\/394\/41916060\/oncolo_22_4_394.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/4\/394\/41916060\/oncolo_22_4_394.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T14:04:09Z","timestamp":1692713049000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/4\/394\/6438804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,17]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,3,17]]},"published-print":{"date-parts":[[2017,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2016-0307","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,4,1]]},"published":{"date-parts":[[2017,3,17]]}}}